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ABSTRACT
ADP-ribosylation is a dynamic post-translation modi-
fication that regulates the early phase of various DNA
repair pathways by recruiting repair factors to chro-
matin. ADP-ribosylation levels are defined by the ac-
tivities of specific transferases and hydrolases. How-
ever, except for the transferase PARP1/ARDT1 little is
known about regulation of these enzymes. We found
that MacroD2, a mono-ADP-ribosylhydrolase, is ex-
ported from the nucleus upon DNA damage, and that
this nuclear export is induced by ATM activity. We
show that the export is dependent on the phospho-
rylation of two SQ/TQ motifs, suggesting a novel di-
rect interaction between ATM and ADP-ribosylation.
Lastly, we show that MacroD2 nuclear export tempo-
rally restricts its recruitment to DNA lesions, which
may decrease the net ADP-ribosylhydrolase activ-
ity at the site of DNA damage. Together, our results
identify a novel feedback regulation between two cru-
cial DNA damage-induced signaling pathways: ADP-
ribosylation and ATM activation.
INTRODUCTION
ADP-ribosylation is a reversible post-translational modifi-
cation implicated in the regulation of several cellular pro-
cesses, such as genomic stability, chromatin structure, tran-
scription and RNA metabolism (1–3). Proteins are most
often ADP-ribosylated by poly(ADP-ribose) polymerases
(PARPs), also known asADP-ribosyltransferase diphtheria
toxin-like proteins (ARTDs), which transfer anADP-ribose
moiety from nicotinamide adenine dinucleotide (NAD+)
onto target proteins, typically in response to various forms
of cellular stress (4,5). The best studied members of the
PARP family––PARP1, PARP2, PARP5a (TNKS1) and
PARP5b (TNKS2) – generate poly(ADP-ribose) (PAR) (3).
The remaining PARP members can only transfer a single
mono(ADP-ribose) (MAR) onto target proteins, with the
exception of two––PARP9 and PARP13––that are enzy-
matically inactive. Besides the MARylating PARPs, the de-
acetylase sirtuins SIRT2, SIRT4 and SIRT6 were also re-
ported to MARylate target proteins (6–8).
The regulation of the ADP-ribosylating enzymes re-
mains poorly understood, and previous studies are es-
sentially limited to PARP1. PARP1 enzymatic activity is
increased by SET7/9-dependent methylation (9), SIRT6-
induced MARylation (10) and cyclin-dependent kinase
2 (CDK2)-dependent phosphorylation (11). But the best
known enhancers of PARP1 activity are DNA lesions (2).
During theDNAdamage response, PARP1 is important for
the repair of both single- and double-strand breaks (DSBs).
DNA damage-induced activation of many pathways also
provides intriguing examples of signal integration involving
ADP-ribosylation. During DSB repair, an interaction be-
tween PARP1 and ataxia-telangiectasia-mutated (ATM) ki-
nase, a member of the PI3K-like kinase family, has been re-
ported. When cells undergo DNA damage, PARP1 is phos-
phorylated atmultiple residues, some of which are targets of
ATM (12–14). Additionally, since ATM contains two PAR-
binding motifs, PAR formation at DNA lesions induces re-
cruitment of ATM (15,16).
The number of enzymes known to reverse ADP-
ribosylation is much smaller. PAR glycohydrolase (PARG)
and ADP-ribosylhydrolase 3 (ARH3) catalyze the degrada-
tion of PAR by hydrolyzing the O-glycosidic ribose-ribose
bonds (3). However, they cannot remove the most proximal
mono(ADP-ribose). MacroD1, MacroD2 and TARG1,
three human enzymes with enzymatic macrodomain, were
shown to reverse protein MARylation (17–19). The in vivo
functions and regulation of these macrodomain hydrolases
remain essentially unknown. MacroD1 has an N-terminal
mitochondrial targeting sequence and localizes within mi-
tochondria, suggesting that its substrates are mitochondrial
as well. Both TARG1 and MacroD2 are present in the nu-
cleus and the cytoplasm (19,20), although they differ in the
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protein sequence. The TARG1 sequence consists only of a
macrodomain, but MacroD2 is twice the size of TARG1,
containing a C-terminal region as long as the macrodomain
itself. Although the exact molecular functions of MacroD2
are unknown, it has been associated with cancer and neu-
rological disorders (21–27).
Published studies have so far focused only on the
MacroD2 macrodomain, showing its recruitment to DNA
lesions (17,18). Since both PARG and TARG1 deficiencies
are associated with neurodegeneration and DNA repair de-
fects (19,28), theMacroD2 associationwith cancer and neu-
rological disorders prompted us to study the behavior of
full-length MacroD2 upon DNA damage.
MATERIALS AND METHODS
Reagents and antibodies
DMSO (D2438––Sigma); etoposide (E1383––Sigma-
Aldrich); PARP inhibitor Olaparib
(AZD2281––Selleckchem); ATM kinase inhibitor
(KU55933––Selleckchem); ATR kinase inhibitor
(VE-821––Selleckchem); DNA-PK kinase inhibitor
(NU7441––Selleckchem); NAMPT inhibitor (FK-
866––Sigma-Aldrich); (32P)ATP (FP-301––Hartmann
Analytic); GFP-trap (gta––Chromotek); bisBenzimide H
33342 trihydrocloride (Hoechst) (Sigma).
Anti-GAPDH (rat monoclonal #5C4 from Dr Krem-
mer of Helmholtz Zentrum Munich); anti-ATM [Y170]
(ab32420, rabbitmonoclonal, Abcam);Alexa-488 goat anti-
rabbit (Invitrogen); goat anti-rabbit IgG-HRP conjugated
(BIO-RAD); anti-rat IgG-HRP conjugated (Jackson Im-
munoResearch). Anti-MacroD2 (rabbit polyclonal #494-
7) was generated by in-house facility, by injecting rabbits
with the purified V5-tagged MacroD2 macrodomain pro-
tein described in (17). Serum was affinity-purified by cou-
pling MacroD2 macrodomain protein to CNBr Sepharose
using standard protocol.
Plasmids
Mammalian expression constructs of wild-type MacroD2
macrodomain was described previously (29). The mam-
malian expression construct of wild-type MacroD2 full
length (aa 1–448) was obtained by PCR from human
testis cDNA library (Clontech) and inserted into the
pmEGFP-C1 vector by using BglII and EcoRI restriction
sites. Wild-type MacroD2 C-terminal domain (aa236–448)
and MacroD2 shorter fragments (aa382–418), (aa402–418)
and (aa410–418) were generated by cloning of the PCR-
amplified corresponding sequence from the above men-
tioned full-length construct into the pmEGFP-C1 vector by
using BglII and EcoRI restriction sites. The following mu-
tants were generated from MacroD2 full-length construct
by using QuikChange site-directed mutagenesis (Strata-
gene) according to the manufacturer’s protocol: S276 345
415 426A; S345 415 426A; S276 415 426A; S276 345 426A;
S276 345 415A. The followingmutants were generated from
MacroD2 (aa382–418): S415A; Q416A. The following mu-
tants were generated from MacroD2 (aa336–372): S345A;
Q346A. All constructs were sequence verified.
Bacterial expression constructs: a pETM-CN vector-
based His6-TEV-mEGFP-tagged human MacroD2 C-
terminal domain (aa236-448) construct was generated by
amplifying the desired fragment from the above men-
tioned pmEGFP-C1-MacroD2 C-terminal region and in-
serting it in the vector with BamHI and XbaI en-
zymes. mEGFP-tagged MacroD2 (aa382–418) was gener-
ated in two versions: pETM-CN-His6-TEV and pGEX-
6P1-GST, generated by inserting the same sequence am-
plified from pmEGFP-MacroD2 (aa382–418) respectively
with BamHI–XbaI and BamHI–EcoRI restriction en-
zymes. Corresponding point mutants of the Hi6-version
were generated through the QuikChange site-directed mu-
tagenesis (Stratagene) protocol: D410A, V411E, E412A,
M413A, N414A, S415A and Q416A. All constructs were
sequence verified.
Cell culture, transfection and siRNA treatment
HumanU2OS cell lines stably expressing mYFP–MacroD2
full length+mCherry-H2B or mEGFP-MacroD2 C-
terminal domain (aa236-448)+mCherryH2B were grown
in DMEM (Sigma) containing 10% (v/v) FBS (Gibco),
2 mM L-glutamine (Sigma), 100 U ml−1 penicillin, 100
g ml−1 streptomycin (Sigma) and 200 g ml−1 G418
(Gibco). For transient transfections, a human HeLa Kyoto
cell line stably expressing mCherry-H2B was used. DNA
transfection was performed by means of Xfect (Clontech)
according to the manufacturer’s recommendations. For
siRNA-mediated MacroD2 and ATM depletion, Negative
Control #2, s44380 and s1708 Silencer Select siRNA
oligonucleotides (Ambion) were used in combination with
Lipofectamine RNAiMAX (ThermoFisher) according to
the manufacturer’s protocol. Cells were tested on the third
day of siRNA treatment.
Live-cell imaging, pulsed-laser microirradiation and image
analysis
Cells were plated in borosilicate 8-well Lab-Tek chambered
cover glasses (ThermoScientific) or in black cycloolefin-
covered 96-well plates (Greiner). During the experiments,
cells were kept at 37◦C in Phenol Red-free Leibovitz’s, a
CO2-independent imaging medium (Sigma) supplemented
with 10% (v/v) FBS (Gibco), 2 mM L-glutamine (Sigma),
100 U ml−1 penicillin and 100 g ml−1 streptomycin
(Sigma). When indicated, inhibitors were added to the cul-
ture medium 30 min before imaging, with the exception
of FK-866, whose incubation started 16 h before imag-
ing. Imaging was performed on a Zeiss AxioObserver Z1
confocal spinning-disk microscope equipped with an Ax-
ioCam HRm CCD camera (Zeiss) through a Zeiss C-
Apochromat 40×/1.2 water-immersion objective or a Zeiss
Plan-Apochromat 20×/0.8 lens. For laser microirradiation,
we used a 355-nmwavelength, diode-pumped, solid-state,
pulsed laser (DPSL-355/14, Rapp OptoElectronics). DNA
damage was induced by focusing the laser to a point or a
line in the nucleus or by adding etoposide for a final con-
centration of 10 M. Cells were imaged every 10 seconds
or 1 minute for 30 min or every 5 min for 100 min.
The time-lapse and the immunofluorescence images were
analysed with CellProfiler 2.0 (30). The mCherry-H2B or
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Hoechst images were used for the segmentation of the nu-
cleus. To quantify protein export upon treatment, back-
ground was first subtracted and the ratio of nuclear inten-
sity over cytoplasmic intensity of GFP-MacroD2 was cal-
culated. For the time-lapse images, the ratio of each time
point was normalised to the first time point. To quantify the
amount of protein recruited to DNA damage site, we regis-
tered the cells withMultiStackReg plugin (http://bradbusse.
net/sciencedownloads.html) in Fiji (http://fiji.sc/Fiji), sub-
tracted the background and normalised the mean intensity
of recruitment area over the mean intensity of the total cell.
Then, we normalised the ratio at each time point to the in-
tensity of the initial time point. To compare nuclear signal
depletion with cytoplasmic signal increase, the analysis was
as described before, but comparing nuclear mean intensity
over cell mean intensity versus cytoplasm mean intensity
over cell mean intensity. Igor Pro (WaveMetrics) or R were
used for analysing and plotting the data.
Immunocytochemistry
U2OS cells were plated in borosilicate 8-well Lab-Tek
chambered cover glasses (ThermoScientific). Treatment
with etoposide 10 M was performed for one hour. Cells
were then fixed and permeabilised with Methanol/Acetone
1:1 solution for 10 min at –20◦C. Blocking was performed
with PBS–Tween 0.1% with BSA 5%. Cells were incu-
bated with the antibody anti-MacroD2 antibody (1:500),
diluted in PBS-Tween 0.1%–BSA 3%, for 1 h at room tem-
perature. Incubation with Alexa-488-conjugated antibody
(1:500) was performed for 1 h at room temperature. Lastly,
cells were incubated with Hoechst 33342 (Sigma) at 200 ng
ml−1 final concentration for 10 minutes.
Protein expression and purification
Protein expression constructs were expressed in Escherichia
coli Rosetta(DE3)pLysS cells at 18◦C for 16 h after 0.2
mM IPTG induction. Cell pellets were snap-frozen in liq-
uid nitrogen and stored at−80◦C. For histidine-tagged pro-
tein purification, the thawed pellet was resuspended in a
lysis/wash buffer (50 mM Tris–Cl, pH 7.5, 0.5 M NaCl, 20
mM imidazole, 1 mMDDT and protease inhibitor cocktail
(Roche)). Lysates were sonicated for 20 × 18 s at medium
setting (Branson) until the lysate was not viscous and cen-
trifuged for 45 min at ∼45 000 g at 4◦C. The supernatant
was exposed to a column with Ni-NTA agarose (Qiagen),
washed three times with 30 ml wash buffer and eluted with
wash buffer containing 500 mM imidazole. The proteins
were dialyzed in storage buffer (25mMTris–Cl, pH7.5, 0.25
M NaCl, 1 mM DTT) with PD-10 columns (17-0851-01;
GE-Healthcare). Peak fractions were confirmed by SDS-
PAGE and Coomassie staining. Concentrations were deter-
mined by Bradford assay (Biorad). For GST-tagged protein
purification, the procedure was as above, with the exception
that glutathione Sepharose 4 Fast Flow (GE-Healthcare)
and 20mM reduced-glutathione elution buffer (GEHealth-
care) were used.
Immunoblotting
RIPA buffer (50 mM Tris–Cl, pH 7.5, 0.15 M NaCl, 0.1%
sodium deoxycholate, 1 mM EDTA, 1% NP-40) was used
to obtain whole cell lysate, whose concentration were de-
termined via a Bradford assay on strongly diluted samples.
Proteins were resolved on 12% or 6% + 12% SDS-PAGE
and transferred onto nitrocellulose membrane (Whatman
Protran). The membrane was blocked in PBS-Tween 0.05%
buffer supplemented with 5% non-fat milk. Proteins were
detected with the appropriate primary antibodies and sec-
ondary antibodies coupled to horseradish peroxidase. De-
tection was performed with Immobilon Western Blotting
detection reagent (GE Healthcare).
Phospho-peptide enrichment upon DNA damage
HumanU2OS cell lines stably expressing mYFP–MacroD2
full length+mCherry-H2B were treated with etoposide 5
M or DMSO for 1 h. Cells were then collected on ice and
treated with lysis buffer (25 mM Tris–Cl, pH 7.5, 0.15 M
NaCl, 0.5% NP-40, 10 mM NaF, 1 mM Na3VO4, phos-
phatase inhibitor cocktail (PhosSTOP – Roche) and pro-
tease inhibitor cocktail (Roche)). Lysates were than diluted
1:5 with dilution buffer (as lysis buffer, but with 0.01% NP-
40). After vigorous centrifugation, the supernatant was col-
lected and the input was kept. Proper amounts of GFP-trap
(Chromotek), previously washed with lysis:dilution buffer,
were incubated with the supernatant for 1 h at 4◦C with
agitation. The beads were then washed two times with ly-
sis:dilution buffer and once with washing buffer (as dilution
buffer, but with 500 mM NaCl). Beads were then kept in
storage buffer (PBS, 100 mM NaF, 10 mM Na3VO4, phos-
phatase inhibitor cocktail (PhosSTOP – Roche) and pro-
tease inhibitor cocktail (Roche)).
Proteomics sample preparation and data analysis
Proteins bound to beads were treated with 5 mM DTT to
reduce disulfide bonds and subsequently alkylated using 20
mM iodoacetamide. Proteins were cleaved with AspN for
12 h at 25◦C. Following proteolytic digest, peptide mix-
tures were desalted on reverse-phase C18 stage tips. 90% of
the peptide mixture was mixed with 2 M glycolic acid for
phosphopeptide enrichment on TiO2 as described in (31),
then loaded onto the prepared TiO2 resin (Glygen). Eluted
phosphopeptide mixtures and peptide mixtures were sepa-
rated on an Ultimate 3000 nano-RP-HPLC coupled to an
LTQ-Orbitrap mass spectrometer (both Thermo-Fisher).
The mass spectrometer was operated in data-dependent ac-
quisition mode with one survey scan for precursor mass de-
tection and up to six MS/MS experiments per cycle. CID-
MS/MS experiments were conducted with multi-stage acti-
vation for neutral loss masses of 32.7, 49 and 98. For MS
acquisition, monoisotopic precursor selection and dynamic
exclusion for 30 s were enabled.
Raw data were searched with MaxQuant versus 1.5
against a human protein database (Uniprot, May 2015)
and an in-house target database containing common tar-
get protein and contaminants. All phosphopeptide hits for
MacroD2weremanually curated. To quantify the phospho-
rylation, peak areas for the most abundant charged states
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for unmodified peptides and phosphopeptides of the tar-
get protein were extracted from the raw data of the peptide
mixture before phosphopeptide enrichment and log2 nor-
malized. Signal strength of unmodified peptides was used
for normalization of the protein amount between control
and treatment experiments of each biological replicate. Pro-
teomics data are available in ProteomeXchange and Pride
(32) with the dataset identifier PXD003712.
Radioactivity kinase assay
HumanU2OS cell lines stably expressing mYFP–MacroD2
full length, mEGFP-MacroD2 macrodomain or mEGFP-
MacroD2 C-terminal domain were collected on ice. For the
kinase assay on purifiedMacroD2 fragments: His-mEGFP-
MacroD2 C-terminal (aa236-448) fragment (200 pmol per
sample); GST-mEGFP-tagged MacroD2 (aa382-418) frag-
ment and His-mEGFP-tagged MacroD2 (aa382-418) frag-
ments (wild-type andmutants) (1 nmol per sample); human
HEK293 T-REx cells (ThermoFisher) were collected on ice.
Cells were resuspended in lysis buffer (25 mM Tris–Cl,
pH 7.5, 0.15 M NaCl, 0.5% NP-40, phosphatase inhibitor
cocktail (PhosSTOP – Roche) and protease inhibitor cock-
tail (Roche)), then incubated on ice for 30 min while me-
chanically lysed by syringe.Where appropriate, KU55933 at
the final concentration of 10 Mwas added. The cell lysate
was then supplemented with 250 U benzonase nuclease
(Sigma), MgCl2 to a final concentration of 4 mM and 2 Ci
(32P)ATP (FP-301 – Hartmann Analytic). The lysate was
incubated at 37◦C for 40 min. It was then cleared from the
chromatinwith amaximum speed centrifugation, diluted by
1:5 with dilution buffer (as lysis buffer, but with 0.01% NP-
40) and the input was kept. Proper amounts of GFP-trap
(Chromotek), previously washed with lysis:dilution buffer,
were incubated with the supernatant for 1 h at 4◦C with
agitation. The beads were then washed two times with ly-
sis:dilution buffer and once with washing buffer (as dilu-
tion buffer, but with 500 mM NaCl). Input and beads were
boiled for 10 min at 95◦C in equal amounts of 2× loading
buffer (125mMTris pH 6.8, 20% glycerol, 2.5% SDS, 0.01%
bromophenol blue). Samples were separated on 1 mm Bis–
Tris, 4–12% acrylamide NuPAGE gel according to the man-
ufacturer’s protocol (Invitrogen).
For the U2OS cell lines experiment, the gel was stained
with Coomassie G-250 and dried. Gels were then imaged
(ImageScanner III – GE Healthcare) and exposed to imag-
ing plates (Fuji Film). For the kinase assay on MacroD2
fragments, the gel was stained and imaged (ImageScanner
III – GE Healthcare). Quantification for the kinase assay
on purified mutant MacroD2 fragments was performed by
defining the intensity of every band. Each His-construct in-
tensity was subtracted of the residual intensity in the His-
S415A mutant, whose radioactivity signal is generated by
the degradation of the upper wild-type-containing band,
when GST-tag is lost. Then, the adjusted His-construct in-
tensities were normalised to the GST-construct intensity of
the same lane, normalised to the wild-type/wild-type ratio
and averaged.
RESULTS
MacroD2 exports from the nucleus upon DNA damage
We previously identified MacroD2 as a mono-ADP-
ribosylhydrolase and showed that its macrodomain recruits
to DNA lesion induced by laser microirradiation (17,18).
To further study the role of MacroD2 upon DNA damage,
we transfected U2OS cells with mEGFP-tagged full-length
MacroD2. The levels ofGFP-taggedMacroD2 decreased in
the nucleus upon UVmicroirradiation-induced DNA dam-
age, a behavior not observed for mEGFP alone (Supple-
mentary Figure S1A and B). The decrease in nuclear flu-
orescence was accompanied by fluorescence increase in the
cytoplasm, consistent with the net export ofMacroD2 from
the nucleus to the cytoplasm upon DNA damage (Supple-
mentary Figure S1C).
The speed of MacroD2 nuclear export was proportional
to the amount of DNA damage induced by laser microirra-
diation (Figure 1A and B).We also confirmedMacroD2 ex-
port in cells treated with the topoisomerase II poison etopo-
side, which induces DNA double-strand breaks (Figure 1C
and D). We next tested if the endogenous MacroD2 is ex-
ported from the nucleus. We developed an in-house anti-
MacroD2 antibody that recognizes endogenous MacroD2
at 70 kDa in U2OS whole cell lysates (Supplementary Fig-
ure S1D). In U2OS cells, endogenous MacroD2 shows nu-
clear depletion upon DNA damage induced with 1 hour
of etoposide treatment, as revealed by immunofluorescence
microscopy (Figure 1E and F).
As DNA damage-induced nuclear export was not ob-
served for TARG1 (19), we hypothesized that the unique
MacroD2 C-terminal region could be involved inMacroD2
localization. Protein secondary structure prediction sug-
gests that the C-terminal domain to be disordered (Fig-
ure 1G; (33)). Since intrinsic disordered regions (IDRs)
frequently play important regulatory roles by providing
binding sites for interacting proteins or through regula-
tion by post-translational modifications, we considered it
an interesting feature of MacroD2 to investigate further.
We compared the export of MacroD2 full-length versus
the macrodomain or the C-terminal fragment in HeLa
cells treated with etoposide (Supplementary Figure S1E).
Both the full-length and the C-terminal IDR constructs ex-
ported, the macrodomain alone did not, identifying the C-
terminal IDR ofMacroD2 as a regulatory regionmediating
the DNA damage-induced export of MacroD2.
ATM kinase activity induces MacroD2 nuclear export
By removing mono-ADP-ribose from target proteins,
MacroD2 regulates ADP-ribosylation (17,18), a post-
translational modification that is quickly produced upon
DNA damage and is linked to both single- and double-
strand break repair pathways (1,2). We first tested if PARy-
lation affected the nuclear export of MacroD2. We inhib-
ited PARylation by treating cells with Olaparib, a potent
inhibitor of PARP1, PARP2, PARP3 and PARP4. While
the treatment abolished the recruitment of MacroD2 to
the site of DNA damage, its nuclear export remained un-
changed (Figure 2A and B). Thus, PARylation does not
trigger MacroD2 nuclear export and the macrodomain is
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Figure 2. ATM kinase activity induces MacroD2 nuclear export. (A) Microirradiation live-cell microscopy of U2OS cells stably expressing mEGFP-
MacroD2 full-length construct and treated with Olaparib 2 M or DMSO. The focus of laser microirradiation is indicated with a yellow circle. Scale bar,
10 m. (B) Quantification of A. (C) Microirradiation live-cell microscopy of U2OS cells stably expressing mEGFP-MacroD2 full-length construct and
treated with KU55933 10 M, VE-821 1 M, NU7441 1 M or DMSO. Scale bar, 10 m. (D) Quantification of C. (E) Quantification of live-cell imaging
experiments with U2OS cells stably expressing mYFP-MacroD2 C-terminal domain, pre-treated with siRNA against ATM or negative control siRNA for
three days and treated with etoposide 10 M. Error bars are 95% confidence interval. One representative experiment with more than 200 cells is shown. (F)
Autoradiography and Coomassie staining of mEGFP-MacroD2 full-length protein purified from stably-expressing U2OS cell lysate, previously treated or
not with benzonase and spiked with (32P) -ATP. (G) Autoradiography and Coomassie staining of mEGFP-MacroD2macrodomain or mEGFP-MacroD2
C-terminal region proteins immunopurified from stably-expressing U2OS cell lysates, previously treated with benzonase and spiked with (32P) -ATP. (H)
Coomassie and autoradiography of mEGFP-MacroD2 C-terminal domain added to HEK293 cell lysate, treated or not with benzonase and KU55933,
spiked with (32P) -ATP and successively immunopurified. (I) Quantification of H IP results in three independent experiments. Error bars, SEM. (J)
Abundance of phosphorylated peptides of mEGFP-MacroD2 immunopurified from U2OS stably expressing the protein and treated with etoposide 10
M or DMSO. Quantification of three independent experiments. Error bars, SEM. Statistics performed with paired t-Test with two-tailed distribution. In
B and D, 50–100 cells were quantified from three independent experiments. Error bars are 95% confidence interval. See also Supplementary Table S1.
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not involved in the process. Furthermore, the recruitment
of MacroD2 to the sites of DNA damage does not facilitate
or hinder its export from the nucleus. There are a number of
other NAD+ utilizing enzymes, among them several mono-
ADP-ribosyl-transferases and sirtuins. To address if a re-
duction of NAD+ levels affected MacroD2 nuclear export,
we pre-treated U2OS cells expressing the mEGFP-tagged
MacroD2 C-terminal fragment with FK866 to inhibit the
activity of the NAMPT enzyme, and thus deplete the cellu-
lar NAD+ pool (34,35). We did not observe any change in
theDNAdamage-induced nuclear export of the C-terminus
ofMacroD2 after NAMPT inhibition (Supplementary Fig-
ure S2A), further supporting the notion that MacroD2 is
exported from the nucleus in a manner independent from
the activity of PARPs and sirtuins.
The PI3K-related kinases––ATM, ATR and DNA-
PK––play a pivotal role in the regulation of the DNA dam-
age response (36). To address if any of the PIKK family
members were responsible for the DNA damage-triggered
MacroD2 export, we pre-treated U2OS cell expressing
mEGFP-MacroD2 with specific inhibitors of ATM, ATR
and DNA-PK, using KU55933, VE-821 and NU7441 re-
spectively, and measured MacroD2 export following laser
microirradiation (Figure 2C and D). The UV microirradi-
ation induced MacroD2 export in the DMSO treated con-
trol, but the ATM inhibitor completely blocked the process.
Neither ATR nor DNA-PK inhibitors reduced MacroD2
nuclear export. ATM inhibition also blocked MacroD2 ex-
port uponDNAdamage induced by etoposide (Supplemen-
tary Figure S2B and C).
To further validate the role of ATM, we tested MacroD2
export after siRNA-mediated knockdown of ATM (Sup-
plementary Figure S2D). The RNAi-mediated depletion of
ATM reduced the export of both the C-terminal construct
and full-length MacroD2 upon etoposide treatment (Fig-
ure 2E; Supplementary Figure S2E). The incomplete block
of MacroD2 export in the ATM depleted cells could be due
to either residual ATM activity or other kinases function-
ally redundant with ATM. To differentiate between these
two possibilities, we measured the etoposide-induced ex-
port of the MacroD2 C-terminal IDR by combining ATM
RNAi with small molecule inhibitors of ATM, ATR or
DNA-PK (Supplementary Figure S2F). The combination
of ATM RNAi treatment and ATM inhibitor successfully
blocked the process. On the other hand, when ATR or
DNA-PK inhibitors are combined with ATM RNAi treat-
ment,MacroD2 exports as fast as the controlDMSO. These
results show that activation of ATM is necessary and suffi-
cient for MacroD2 export upon DNA damage.
ATM activation leads to phosphorylation of theMacroD2 C-
terminal region
Considering that ATM activation generates a cascade
of phosphorylation events (15), we wanted to test if
MacroD2 is phosphorylated upon DNA damage. By using
(32P)ATP, we induced DNA damage by adding benzonase
nuclease to the extract from U2OS cells stably expressing
MacroD2 constructs (Figure 2F). No radioactivity was de-
tected in case of the macrodomain-only construct, indicat-
ing that the C-terminal part of the protein is the primary
target of the modification (Figure 2G). Also, when we in-
cubated the purifiedmEGFP-taggedMacroD2 C-terminal-
fragment in HEK293 lysate treated with benzonase nu-
clease, the radioactive signal of MacroD2 is decreased, if
KU55933 is added to the reaction (Figure 2H and I).
To further confirm the DNA damage-induced phospho-
rylation of MacroD2, we adopted a mass-spectrometry-
based phospho-proteomics approach measuring the abun-
dance of phosphorylated peptides from MacroD2 in sam-
ples with or without etoposide treatment. Among a selec-
tion of peptides (70% sequence coverage), some sites in
MacroD2 showed increased phosphorylation upon etopo-
side treatment as compared with control, like S415 and
S426 (Figure 2J; Supplementary Table S1). In particular, the
phosphorylated version of the peptide 402–417 is highly en-
riched upon etoposide treatment and, given the short size of
the peptide and the absence of other compatible residues,
the phosphorylation occurs at S415. Based on the mass-
spectrometry data, we estimated that∼14% of peptide 402–
417 is phosphorylated upon etoposide treatment (Supple-
mentary Table S1). Assuming that the ratio of the nuclear
and cytoplasmic volumes is about 1:4 and that upon etopo-
side treatment around 60%of the nuclearMacroD2 remains
in the nucleus, it means that only about 12% of the total
pool ofMacroD2 protein remains in the nucleus after DNA
damage. The level of observed MacroD2 phosphorylation
upon DNA damage would be consistent withMacroD2 be-
ing mostly present as phosphorylated on S415 in the nu-
cleus where ATM kinase activity dominates while in the cy-
toplasm, S415 of MacroD2 is efficiently dephosphorylated
and is predominantly in a non-phosphorylated state.
Sequence requirements for the phosphorylation are consistent
with the direct involvement of ATM
The C-terminal region of MacroD2 is rich in serine and
threonine residues, with four of the serines followed by glu-
tamine (Figure 3A for a schematic view). The SQ/TQmotif
is indeed a consensus target of ATM and other PIKKmem-
bers (37). When we mutated all four serine residues within
the SQ motifs to alanine (mutant 4SA), MacroD2 nuclear
export upon DNA damage was blocked (Figure 3B and C).
To address the specific contribution of each motif to nu-
clear export, we created four mutants, each with three of
the four serinesmutated to alanine, leaving only one SQmo-
tif intact per construct (Figure 3D; Supplementary Figure
S3A). We found both S345 and S415 alone to be sufficient
for MacroD2 nuclear export, even though their export rate
did not reach that of wild type, indicating that the two re-
gions act co-operatively.
We sought to further characterize the importance of
residues in the export-competent region. We decided to fo-
cus on serine 415, since this serine was the best character-
ized in our phospho-proteomics analysis. We tested a se-
ries of fragments with decreasing length to find a sequence
short enough to be further manipulated but still able to ex-
port (Supplementary Figure S3B and C). We found that
the 9-residue-long fragment between amino acids 410–418
showed strongly reduced, yet measurable export. Next, we
addressed to what extent each residue in this sequence is re-
quired for phosphorylation. To this end, we adopted a scan-
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Figure 3. Sequence requirements for the phosphorylation are consistent with the direct involvement of ATM. (A) Schematic view showing the four SQmo-
tifs present on the C-terminal domain. (B) Microirradiation live-cell microscopy of HeLa cells transfected with mEGFP-MacroD2 full-length or mEGFP-
MacroD2 S276,345,415,426A constructs. Scale bar, 10 m. (C) Quantification of B. (D) Quantification of microirradiation live-cell microscopy of HeLa
cells transfected with mEGFP-MacroD2 full length or the different serine triple mutants (Examples shown in Supplementary Figure S3A). (E) Coomassie
and autoradiography ofGST-mEGFP-MacroD2 (aa382–418)wild-type andHis-mEGFP-MacroD2 (aa382–418) (wild-type ormutant proteins) immunop-
urified fromHEK293 cell lysate, treated with benzonase and spiked with (32P) -ATP. (F) Quantification of E in three independent experiments. Error bars,
SEM. Statistics performed with unpaired non-parametrical Mann-Whitney test against the wild-type. *P ≤ 0.05; n.s. is P > 0.05. (G) Microirradiation
live-cell microscopy of HeLa cells transfected with mEGFP-MacroD2 (aa382–418) wild-type construct or mutations of S415A or Q416A. Scale bar, 10
m. (H) Quantification of G. In C,D and G, 50–100 cells were quantified from three independent experiments. Error bars are 95% confidence interval. See
also Supplementary Figure S3.
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ning mutagenesis approach, mutating each residue of the
410–416 stretch to alanine (or aspartate in the case of V411)
within themEGFP-MacroD2 (382–418) fragment. To assay
the kinase activity, we used HEK293 cell lysates spiked with
the purified proteins and treated with benzonase nuclease.
We tested the incorporation of (32P)-phosphate in the His-
mEGFP-tagged mutagenized fragments compared to the
GST-mEGFP-tagged wild-type fragment, which acted as
an internal positive control for phosphorylation (Figure 3E
and F). We confirmed that the mutations of either S415 or
Q416 impair the phosphorylation of the fragments. Finally,
we tested the mutation of S415 or Q416 with a mEGFP-
tag in export assays upon UV microirradiation (Figure 3G
andH). Significantly, both S415 and Q416 are necessary for
nuclear export, which is also the case for S345 and Q346
(Supplementary Figure S3D). Our experiments reveal that
two of the four SQ motifs in the C-terminal IDR are cru-
cial for MacroD2 nuclear export and appear to work in an
additive manner. The observation that both the serine and
the glutamine are crucial for both the phosphorylation and
the export of MacroD2, strongly suggests that MacroD2 is
a direct target of ATM kinase.
ATM activity regulates the recruitment of MacroD2 to sites
of DNA damage
Lastly, we addressed if the ATM-induced MacroD2 nu-
clear export could affect MacroD2 recruitment to sites
of DNA damage. We compared the recruitment dynam-
ics of mEGFP-tagged MacroD2 full-length, MacroD2
macrodomain andMacroD2 C-terminus proteins uponUV
microirradiation (Figure 4A). Both MacroD2 full-length
andmacrodomain recruited toDNAdamage sites, while the
mEGFP-MacroD2 C-terminus fragment did not. But re-
cruitment at the DNA lesion differs betweenMacroD2 full-
length and MacroD2 macrodomain, since the full-length
protein is dissipated faster than the macrodomain version.
To assess whether MacroD2 nuclear export impacts on the
recruitment dynamics, we compared the accumulation of
EGFP-tagged wild type MacroD2 with that of the export-
incompetent (4SA) mutant at the UV microirradiated sites,
in the presence of the ATM inhibitor, KU55933, or DMSO
control (Figure 4B and C). MacroD2 full-length recruit-
ment peaked 2 min after laser irradiation. Afterwards,
the protein amount at the sites of DNA damage––and
within the whole nucleus––decreased, which led to the loss
of MacroD2 proteins at the damage site within 5 min.
Both ATM inhibition and export-abolishing mutations in
MacroD2 resulted in longer retention of MacroD2 at the
DNA damage sites: recruitment was detected until the
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end of the experiment (30 minutes). These results suggest
that nuclear ADP-ribosylation could be modulated upon
DNA damage through the ATM-induced nuclear export of
MacroD2.
DISCUSSION
We found that MacroD2 is exported from the nucleus
upon DNA damage and that this depends on the ATM-
induced phosphorylation of theMacroD2C-terminal IDR.
The export-inducing phosphorylation occurs on two serine
residues, both followed by glutamine, and these SQ/TQmo-
tifs aremodified by the PI3K-like kinases (37). The observa-
tion that the glutamine after the serine is absolutely required
for phosphorylation and consequently nuclear export sug-
gests that MacroD2 is a direct target of ATM.
ATM kinase is involved in the initial steps of DNA dam-
age signaling and coordinates different cellular pathways
to achieve either cell survival or apoptosis (15). Among its
many effects, ATM activation can induce changes in the
subcellular localization of a number of proteins, either di-
rectly or indirectly, such as the NF-B essential modula-
tor, NEMO, or the p53-ubiquitin ligase COP1 (38,39). Like-
wise, ATM induces the regulation ofMacroD2 localization.
Still, the sequences surrounding MacroD2 SQ motifs differ
from those previously described proteins, suggesting that
the MacroD2 mode of export employs a different export
mechanism.
Importantly, our findings indicate that the ATM-
dependent MacroD2 nuclear export creates an addi-
tional regulatory node between ATM signaling and ADP-
ribosylation upon DNA damage. In recent years, several
factors involved in homology-driven repair and ATM sig-
naling – among them ATM itself – have been shown to
recruit to DNA breaks thanks to PAR-binding motifs
(2). For example, NBS1 and MRE11 recruitment depends
on PARP1 activation, and the formation of the MRE11-
RAD50-NBS1 (MRN) complex is pivotal for ATM activa-
tion (40). Due to ATM-induced MacroD2 nuclear export,
MacroD2 is cleared faster from the sites of DNA damage
as compared to without export, suggesting that ATM acti-
vation alters ADP-ribosylation dynamics. The role of ATM
in the clearance of MacroD2 from DNA lesions might be
linked with the oncogenic features recently associated to
MacroD2, where MacroD2 is found to be over-expressed
in tamoxifen-resistant and estrogen-independently growing
breast cancer cell lines (21). Thus, how the nuclear export
of MacroD2 modulates the ADP-ribosylated proteins, and
consequently the DNA damage response, will be the next
important step in understanding the underlying molecu-
lar mechanisms of this novel crosstalk between two crucial
DNA damage-induced signalling pathways.
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